University of Alabama at Birmingham, University of Alabama
76 papers in the library · 2,937 citations · publishing 2014-2026
JAMA Health Forum November 1, 2024 Otto Simonsson, Matthew W. Johnson, Peter S. Hendricks 10 citations
This Viewpoint discusses the need to better understand potential risks associated with psychedelic and 3,4-methylenedioxymethamphetamine (MDMA) use to ensure safe and ethical practice and identifies 4 key research goals.
J Psychopharmacol October 29, 2024 Otto Simonsson, Simon B. Goldberg, Peter S. Hendricks 4 citations
Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.
Journal of Drug Issues August 22, 2024 Heith Copes, Andrew Hochstetler, Jared Ragland et al. 3 citations
Our aim is to understand how those who use peyote in a naturalistic setting discuss it changed their lives and to what they attribute this change. To do this, we draw on data from a photo-ethnography of people who attended peyote ceremonies in rural Northcentral Alabama. Broadly, we found that participants discussed four core areas of change: reduced drug and alcohol misuse, new perspectives on...
Scientific Reports August 2, 2024 Jennifer Mitchell, Nicky J. Mehtani, Mallory O. Johnson et al. 9 citations
Abstract As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic , in part due to limited success...
Psychological Medicine April 1, 2024 Otto Simonsson, Walter Osika, Cecilia U.D. Stenfors et al. 15 citations
Previous research has proposed that there may be potential synergies between psychedelic and meditation interventions, but there are still knowledge gaps that merit further investigation. Using a longitudinal observational research design with samples representative of the US and UK adult population with regard to sex, age, and ethnicity (N = 9732), we investigated potential associations...
Journal of Psychoactive Drugs February 10, 2024 Alyssa F. Harlow, Peter S. Hendricks, Adam M. Leventhal et al. 6 citations
Despite common depictions in the media, there is little scientific evidence on microdosing psychedelic drugs. We assessed awareness, prevalence, and dosing practices of microdosing psychedelic drugs among young adults 18-22 years old from Southern California (2018-2019). We examined whether sociodemographic factors, personality traits, mental health, or other substance use behaviors were...
Journal of Affective Disorders January 26, 2024 Ludwig Honk, Cecilia U.D. Stenfors, Simon B. Goldberg et al. 41 citations
It has long been speculated that psychedelic use could provoke the onset of psychosis, but there is little evidence to support this conjecture. Using a longitudinal research design with samples representative of the US and UK adult populations with regard to sex, age, and ethnicity (n = 9732), we investigated associations between psychedelic use and change in the number of psychotic symptoms...
Am J Psychiatry 2024 Kelley C. O’donnell, Brian T Anderson, Frederick S. Barrett et al. 31 citations
Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.
Pharmacological Research 2024 David B. Yaden, Andrea P Berghella, Peter S. Hendricks et al. 12 citations
Substance use disorders (SUDs) have an enormous impact on public health. With classic psychedelic-assisted therapies showing initial promise in treating multiple SUDs, it is possible that these treatments will become legally available options for patients with SUDs in the future. This article highlights how classic psychedelic-assisted therapies might be integrated into current clinical...
Journal of psychopharmacology (Oxford, England) 2024 Otto Simonsson, Peter S. Hendricks, Cecilia Ud Stenfors et al.
Whereas findings from case reports and cross-sectional studies suggest that naturalistic psychedelic use may be associated with unusual visual experiences that occur after the acute pharmacological effects have subsided, such findings need to be replicated in longitudinal studies to better understand potential cause-and-effect relationships. To investigate longitudinal associations between...
2024 Jo-Hanna Ivers, Katy Tobin, Colm Harrington et al.
OBJECTIVES Understanding variations in knowledge and attitudes of psychiatrists to psilocybin therapy is important for the collective discourse about the potential impact on clinical practice and public health in Ireland. METHODS A 28-item questionnaire was designed based on previous studies and distributed to psychiatrists in Ireland via online mailing lists and at in-person academic events....
Psychedelic Med (New Rochelle) December 13, 2023 Nicholas A. Carlisle, Haley Maria Dourron, Sarah Maccarthy et al. 12 citations
Exploring the Unique Therapeutic Potential of Psychedelics to Reduce Chronic Shame Among Sexual and Gender Minority Adults.
Psychedelic Med (New Rochelle) December 13, 2023 David E. Nichols, Peter S. Hendricks, Charles D. Nichols 1 citation
If Everything Is Psychedelic, Then Nothing Is: A Response to O'Donnell et al. and Lepow et al.
Psychopharmacology December 11, 2023 Haley Maria Dourron, Charles D. Nichols, Otto Simonsson et al. 23 citations
5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity,...
Psychedelic Med (New Rochelle) September 13, 2023 Jacob S. Aday, Brian S. Barnett, Dan Grossman et al. 56 citations
Background: In the wake of positive clinical trial outcomes of psychedelic-assisted psychotherapy for the treatment of various psychiatric disorders, there has been an influx of financial investment into psychedelic drug development from the pharmaceutical and biotech sectors. Psychedelics are now a multibillion dollar industry, with hundreds of companies that are seeking to commercialize...
Psychedelic Med (New Rochelle) September 13, 2023 Peter S. Hendricks, Charles D. Nichols 6 citations
The Elephant in the Room: Personal Use of Psychedelics Among Psychedelic Researchers.
Journal of Psychoactive Drugs August 31, 2023 Haley Maria Dourron, Heith Copes, Agasthya Vedre-Kyanam et al. 6 citations
Deliriants are the least studied class of hallucinogens and display noticeable subjective effects, including dysphoria, hallucinations, and substantial alterations in thought. High doses of diphenhydramine (DPH), an over-the-counter antihistamine medication, can produce deliriant effects due to secondary anticholinergic activity. We sought to characterize the subjective experiences produced by...
Neuropharmacology April 2, 2023 Farah Z Zia, Michael H. Baumann, Sean J Belouin et al. 28 citations
Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the United States. For many people, pain can be satisfactorily managed by existing medicines and comprehensive psychosocial treatments. For others, available treatments are either ineffective or not acceptable, due to side effects and concerns about risks....
Journal of Affective Disorders April 1, 2023 Otto Simonsson, Peter S. Hendricks, Richard Chambers et al. 124 citations
Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics,...
Mindfulness April 1, 2023 Charlotta Simonsson, Richard Chambers, Peter S. Hendricks et al. 15 citations
Previous research has investigated potential synergies between classic psychedelics and meditation practice, but relatively little remains known about the relationship between classic psychedelic experiences and engagement with meditation practice.The purpose of this study was to investigate associations between classic psychedelic experiences and engagement with two popular types of...
Psychedelic Med (New Rochelle) March 13, 2023 David E. Nichols, Charles D. Nichols, Peter S. Hendricks 39 citations
Proposed Consensus Statement on Defining Psychedelic Drugs.
Psychedelic Med (New Rochelle) March 13, 2023 Peter S. Hendricks, Charles D. Nichols, Kathryn A. Cunningham et al. 7 citations
Past, Present, and Future of Psychedelics: A Psychedelic Medicine Roundtable Discussion.
JAMA Psychiatry 2023 Brian D Kiluk, Bethea A Kleykamp, Sandra D Comer et al. 22 citations
Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous μ-opioid receptor (MOR) system. The goal of this review is to highlight unique clinical trial design considerations for the study of emerging treatments for OUD that address targets beyond the MOR system. In...
Drug Science Policy and Law 2023 Brian S. Barnett, Noah Wiles Sweat, Peter S. Hendricks 6 citations
Background Recent survey data indicate that some people report long-term improvement in color vision deficiency (CVD), also known as color blindness, following use of psychedelics such as lysergic acid diethylamide (LSD) and psilocybin. However, there are no objective data reported in the medical literature quantifying the degree or duration of CVD improvement associated with psychedelic use....
Expert Review of Neurotherapeutics 2023 Emmanuelle A. D. Schindler, Peter S. Hendricks 5 citations
While the majority of current research and development surrounds depression, demoralization, and substance use disorders, there are numerous reports of psychedelics having beneficial effects in other branches of medicine, including for headache disorders and chronic pain. This perspective reviews conventional forms of treatment for headache and other chronic pain disorders and describes...